These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 30240146)

  • 1. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.
    Tsiatas M; Kalogeras KT; Manousou K; Wirtz RM; Gogas H; Veltrup E; Zagouri F; Lazaridis G; Koutras A; Christodoulou C; Pentheroudakis G; Petraki C; Bafaloukos D; Pectasides D; Kosmidis P; Samantas E; Karanikiotis C; Papakostas P; Dimopoulos MA; Fountzilas G
    Cancer Med; 2018 Oct; 7(10):5066-5082. PubMed ID: 30240146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
    Koletsa T; Kotoula V; Koliou GA; Manousou K; Chrisafi S; Zagouri F; Sotiropoulou M; Pentheroudakis G; Papoudou-Bai A; Christodoulou C; Xepapadakis G; Zografos G; Petraki K; Pazarli E; Koutras A; Kourea HP; Bafaloukos D; Chatzopoulos K; Iliadis A; Markopoulos C; Venizelos V; Arnogiannaki N; Kalogeras KT; Kostopoulos I; Gogas H; Fountzilas G
    Cancer Immunol Immunother; 2020 Aug; 69(8):1549-1564. PubMed ID: 32303794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
    Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
    Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
    Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
    Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune characterization of breast cancer metastases: prognostic implications.
    Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
    Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
    Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
    Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer.
    Ahn S; Chung YR; Seo AN; Kim M; Woo JW; Park SY
    PLoS One; 2020; 15(5):e0233037. PubMed ID: 32401825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration.
    Liu S; Foulkes WD; Leung S; Gao D; Lau S; Kos Z; Nielsen TO
    Breast Cancer Res; 2014 Sep; 16(5):432. PubMed ID: 25193543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.
    Li J; Wang J; Chen R; Bai Y; Lu X
    Oncotarget; 2017 Feb; 8(9):15621-15631. PubMed ID: 28152503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    Gao G; Wang Z; Qu X; Zhang Z
    BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ localization of tumor cells associated with the epithelial-mesenchymal transition marker Snail and the prognostic impact of lymphocytes in the tumor microenvironment in invasive ductal breast cancer.
    Alkatout I; Hübner F; Wenners A; Hedderich J; Wiedermann M; Sánchez C; Röcken C; Mathiak M; Maass N; Klapper W
    Exp Mol Pathol; 2017 Apr; 102(2):268-275. PubMed ID: 28232080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis.
    Yao W; He JC; Yang Y; Wang JM; Qian YW; Yang T; Ji L
    Sci Rep; 2017 Aug; 7(1):7525. PubMed ID: 28790445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
    Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
    Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
    Blok EJ; Engels CC; Dekker-Ensink G; Meershoek-Klein Kranenbarg E; Putter H; Smit VTHBM; Liefers GJ; Morden JP; Bliss JM; Coombes RC; Bartlett JMS; Kroep JR; van de Velde CJH; Kuppen PJK
    Breast Cancer Res Treat; 2018 Aug; 171(1):65-74. PubMed ID: 29766362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.
    Psyrri A; Kalogeras KT; Wirtz RM; Kouvatseas G; Karayannopoulou G; Goussia A; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Economopoulou P; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
    J Transl Med; 2017 Feb; 15(1):30. PubMed ID: 28193231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Role of Tumor-Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma.
    Wongpattaraworakul W; Choi A; Buchakjian MR; Lanzel EA; Kd AR; Simons AL
    BMC Cancer; 2024 Jun; 24(1):766. PubMed ID: 38926643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.